Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

2 Apr 2015 16:55

RNS Number : 3808J
Epistem Holdings plc
02 April 2015
 



 

 

 

 

 

Epistem Holdings Plc ("Epistem" or the "Company")

 

Directors' Shareholdings

 

Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.

 

As a result of the subscription for Partnership Shares and the award of Matching Shares, executive Directors, Matthew Walls, Dr Catherine Booth, John Rylands and Dr Allan Brown each increased their beneficial interests in the Company by 450 ordinary shares of 1.5p each. These shares were acquired on 28 January 2015, 27 February 2015 and 27 March 2015 at prices of 273p, 260p and 225p respectively.

Following these transactions, the current beneficial interests of the executive Directors are set out below:

 

Ordinary Shares %

 

Matthew Walls 12,820 0.13%

Dr Catherine Booth 987,175 9.87%

John Rylands 197,073 1.97%

Dr Allan Brown 1,761 0.01%

 

Epistem further announces that it was informed on 2 April 2014 that, on that day, Dr Catherine Booth transferred 2,983 ordinary shares of 1.5 pence each to her Self Invested Personal Pension fund at a price of 225p Following this transaction, Dr. Catherine Booth's beneficial interest remains unchanged at 987,175 ordinary shares representing 9.87% of the Company's issued share capital.

 

 

 

For further details please contact:

 

Epistem Holdings Plc

Matthew Walls: Chief Executive Officer ++44 (0)161 606 7258

John Rylands: Finance Director

 

Peel Hunt LLP

James Steel ++44 (0)207 418 8900

Clare Terlouw

 

Walbrook PR

Mike Wort ++44 (0)207 933 8780

Anna Dunphy

 

Please see http://www.epistem.co.ukfor additional information.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBUGDSDUGBGUD
Date   Source Headline
10th Sep 20214:35 pmRNSPrice Monitoring Extension
10th Sep 20212:01 pmRNSProposed Placing and Open Offer
31st Aug 20217:00 amRNSNew Genedrive system readied for AIHL launch
1st Jul 20217:00 amRNSGenedrive COVID-19 Point of Care device update
25th Jun 20214:40 pmRNSSecond Price Monitoring Extn
25th Jun 20214:35 pmRNSPrice Monitoring Extension
25th Jun 20211:17 pmRNSGenedrive confirms receipt of India Import License
25th Jun 202111:05 amRNSSecond Price Monitoring Extn
25th Jun 202111:00 amRNSPrice Monitoring Extension
22nd Jun 202111:05 amRNSSecond Price Monitoring Extn
22nd Jun 202111:00 amRNSPrice Monitoring Extension
28th May 20216:00 pmRNSBlock listing Interim Review
28th May 20214:40 pmRNSSecond Price Monitoring Extn
28th May 20214:35 pmRNSPrice Monitoring Extension
6th May 20212:05 pmRNSSecond Price Monitoring Extn
6th May 20212:00 pmRNSPrice Monitoring Extension
30th Apr 20217:00 amRNSCOVID-19 PCR test approved by Indian regulator
23rd Apr 20217:00 amRNSExcellent performance data for Genedrive® HCV test
19th Apr 20217:00 amRNSPHE National Framework Agreement
1st Apr 20217:00 amRNSTotal Voting Rights
31st Mar 202111:05 amRNSSecond Price Monitoring Extn
31st Mar 202111:00 amRNSPrice Monitoring Extension
25th Mar 20217:00 amRNSHalf-year Report
9th Mar 20217:00 amRNSDistribution agreement
3rd Mar 20217:00 amRNSAntibiotic Induced Hearing Loss update
1st Mar 20214:41 pmRNSSecond Price Monitoring Extn
1st Mar 20214:35 pmRNSPrice Monitoring Extension
1st Mar 20217:00 amRNSInvestor Presentation
1st Mar 20217:00 amRNSTotal Voting Rights
17th Feb 20217:00 amRNSFirst US shipments of Genedrive® 96 SARS-CoV-2 Kit
12th Feb 20212:10 pmRNSHolding(s) in Company
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
9th Feb 20212:28 pmRNSHolding(s) in Company
8th Feb 20213:30 pmRNSHolding(s) in Company
8th Feb 202112:51 pmRNSHolding(s) in Company
8th Feb 202111:05 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
2nd Feb 20212:05 pmRNSHolding(s) in Company
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20211:22 pmRNSHolding(s) in Company
1st Feb 20219:05 amRNSSecond Price Monitoring Extn
1st Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20219:05 amRNSSecond Price Monitoring Extn
29th Jan 20219:00 amRNSPrice Monitoring Extension
28th Jan 20219:05 amRNSSecond Price Monitoring Extn
28th Jan 20219:00 amRNSPrice Monitoring Extension
28th Jan 20217:00 amRNSDistribution agreement with Beckman Coulter

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.